Work

A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps668

Authors: Rachel A. Freedman, Ines Maria Vaz Duarte Luis, William Thomas Barry, Ian E. Krop, Nikhil Wagle, Alarice Lowe, Sarah Galler, Jessica Sohl, Steven J. Isakoff, Nadine M. Tung, Eric P. Winer, Nancy U. Lin

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2586579566

Cites:

Cited by: 1

Related to: 10